Table 2. Performances of our model, the clinical model, and the radiomics model in the training dataset.
| Methods | AUC (%) | ACC (%) | SEN (%) | SPE (%) | F1 (%) |
|---|---|---|---|---|---|
| EGFR | |||||
| Clinical model | 71.29 | 69.25 | 66.72 | 78.64 | 77.37 |
| Radiomics model | 76.46 | 77.23 | 77.96 | 73.62 | 79.78 |
| Our model | 86.56 | 79.43 | 78.27 | 81.35 | 82.59 |
| KRAS | |||||
| Clinical model | 72.56 | 70.67 | 69.48 | 72.09 | 72.55 |
| Radiomics model | 79.63 | 76.59 | 78.19 | 77.67 | 79.76 |
| Our model | 78.97 | 72.25 | 71.81 | 74.26 | 80.94 |
EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma; AUC, area under the curve; sensitivity; ACC, accuracy; SEN, sensitivity; SPE, specificity.